ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is X4 Pharmaceuticals, Inc. ?
1
Flat results in Sep 25
- NET PROFIT(HY) At USD -57.52 MM has Grown at -260.72%
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -51.57%, its profits have fallen by -275.9%
3
Rising Promoter Confidence
- Promoters have increased their stake in the company by 19.89% over the previous quarter and currently hold 21.8% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
4
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 14.90% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -51.57% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to X4 Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is X4 Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
X4 Pharmaceuticals, Inc.
-55.85%
0.11
2716.53%
S&P 500
16.12%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
62.49%
EBIT Growth (5y)
-32.42%
EBIT to Interest (avg)
-19.27
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.17
Tax Ratio
2.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.12%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.05
EV to EBIT
-2.69
EV to EBITDA
-2.73
EV to Capital Employed
16.16
EV to Sales
7.83
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-600.74%
ROE (Latest)
-168.87%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
NET SALES(HY)
At USD 3.74 MM has Grown at 232.86%
RAW MATERIAL COST(Y)
Fallen by -76.12% (YoY
-9What is not working for the Company
NET PROFIT(HY)
At USD -57.52 MM has Grown at -260.72%
Here's what is working for X4 Pharmaceuticals, Inc.
Net Sales
At USD 3.74 MM has Grown at 232.86%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Raw Material Cost
Fallen by -76.12% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for X4 Pharmaceuticals, Inc.
Net Profit
At USD -57.52 MM has Grown at -260.72%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
